What Is Q32 Bio Inc. (QTTB) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Q32 Bio Inc.'s intrinsic value is estimated at $10.32, suggesting the stock is overvalued at its current price of $15.70. With 9 out of 12 models flagging downside (-34.2% average return), the market may be pricing in unsustainable growth. The most optimistic model, First Chicago, places fair value at $19.26 (+22.7%), while EPV — the most conservative — estimates $2.43 (-84.5%). This +107.2% gap reflects genuine analytical uncertainty about Q32 Bio Inc.'s intrinsic worth.
What Do the Models Say About QTTB?
12 of 13 models are currently active for QTTB. Of these, 3 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates QTTB's intrinsic value at $6.69, implying -57.4% downside from the current price. See which stocks rank higher →
How Does QTTB Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, QTTB ranks #135 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Q32 Bio Inc. competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is QTTB a Value Trap?
CirclFi's Value Trap algorithm assigns QTTB a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Q32 Bio Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Q32 Bio Inc. is rated at 5.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +107.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every QTTB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across QTTB's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad